4.7 Article

Identification of Alzheimer's disease using a convolutional neural network model based on T1-weighted magnetic resonance imaging

Journal

SCIENTIFIC REPORTS
Volume 10, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41598-020-79243-9

Keywords

-

Funding

  1. Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI09C1379 (A092077)]
  2. Institute for Information & communications Technology Promotion (IITP) - Korea government (MSIT) [2018-2-00861]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  4. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering
  7. AbbVie
  8. Alzheimer Association
  9. Alzheimer Drug Discovery Foundation
  10. Araclon Biotech
  11. BioClinica, Inc.
  12. Biogen
  13. Bristol-Myers Squibb Company
  14. CereSpir, Inc.
  15. Cogstate
  16. Eisai Inc.
  17. Elan Pharmaceuticals, Inc.
  18. Eli Lilly and Company
  19. EuroImmun
  20. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  21. Fujirebio
  22. GE Healthcare
  23. IXICO Ltd.
  24. Janssen Alzheimer Immunotherapy Research & Development, LLC
  25. Johnson & Johnson Pharmaceutical opuDiagnostics, LLC
  26. NeuroRx Research
  27. Neurotrack Technologies
  28. Novartis Pharmaceuticals Corporation
  29. Pfizer Inc.
  30. Piramal Imaging
  31. Servier
  32. Takeda Pharmaceutical Company
  33. Transition Therapeutics
  34. Canadian Institutes of Health Research

Ask authors/readers for more resources

The classification of Alzheimer's disease (AD) using deep learning methods has shown promising results, but successful application in clinical settings requires a combination of high accuracy, short processing time, and generalizability to various populations. In this study, we developed a convolutional neural network (CNN)-based AD classification algorithm using magnetic resonance imaging (MRI) scans from AD patients and age/gender-matched cognitively normal controls from two populations that differ in ethnicity and education level. These populations come from the Seoul National University Bundang Hospital (SNUBH) and Alzheimer's Disease Neuroimaging Initiative (ADNI). For each population, we trained CNNs on five subsets using coronal slices of T1-weighted images that cover the medial temporal lobe. We evaluated the models on validation subsets from both the same population (within-dataset validation) and other population (between-dataset validation). Our models achieved average areas under the curves of 0.91-0.94 for within-dataset validation and 0.88-0.89 for between-dataset validation. The mean processing time per person was 23-24 s. The within-dataset and between-dataset performances were comparable between the ADNI-derived and SNUBH-derived models. These results demonstrate the generalizability of our models to different patients with different ethnicities and education levels, as well as their potential for deployment as fast and accurate diagnostic support tools for AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available